RET and colorectal carcinoma: Notably, known therapeutically targetable fusions were identified in 7 cases (5.9%): two CRCs with TPM1-NTRK1 fusion, one STS with PEAR1-NTRK1 fusion, one CRC with NCOA4-RET fusion, one GC and one BTC with FGFR3-TACC3 fusion, and one BTC with FGFR2-NRAP fusion.